¼¶±ð: Ôº³¤
UID: 74482
¾«»ª: 0
·¢Ìû: 1326
ÍþÍû: 15 µã
»ý·Öת»»
ÓÞÓÞ±Ò: 1412 YYB
ÔÚÏß³äÖµ
¹±Ï×Öµ: 0 µã
ÔÚÏßʱ¼ä: 33(Сʱ)
×¢²áʱ¼ä: 2009-08-19
×îºóµÇ¼: 2022-08-22
Â¥Ö÷  ·¢±íÓÚ: 2017-05-10 16:25

 PD-1ºÍPD-L1¿¹ÌåÔÚ°©Ö¢ÖÎÁÆÖеÄÏÖ×´ÓëδÀ´

Ëæ׎üÆÚPD-1/PD-L1Öá×è¶Ï×÷ÓÃÓÚʵÌåÁöÊÔÑéµÄ³É¹¦£¬ÃâÒßÁÆ·¨ÔÚ°©Ö¢ÖÎÁÆÖÐÒÑÉýÖÁÖÐÐĵØλ¡£³ÌÐòÐÔËÀÍöÊÜÌå-1»òDP-1ÊÇTϸ°ûÉϵļì²éµã·Ö×Ó£¬ÔÚÕý³£ÈËÌåÖУ¬¶ÔÏÞÖÆÊÊÓ¦ÐÔÃâÒß¡¢×èÖ¹×ÔÉíÃâÒßÓë×ÔÉíÑ×ÐÔ·´Ó¦Æð×ÅÖØÒª×÷Óá£ÔÚ±¾ÎÄÖУ¬ÎÒÃǽ«¼ò¶Ì¸ÅÀ¨Ö§³Ö¿ª·¢PD-1/PD-L1×è¶Ï¼ÁµÄ¿Æѧ±³¾°£¬È»ºóÃèÊöÕâÀ࿹ÌåÔÚ¸÷×éÖ¯ÖдÓÖÎÁƺÚÉ«ËØÁöºÍ·Î°©µ½·Ç³£¼û°©Ö¢µÄ¹ì¼£¼Ç¼£¬ÒÔ¼°¿ÉЭÖúɸѡ²¡»¼µÄÉúÎï±ê¼ÇÎï¡£

    ±³¾°½éÉÜ

    PD-1»ò³ÌÐòËÀÍö-1ÔÚ1992ÄêÊ×´Î×÷Ϊ»ùÒò±»·¢ÏÖ²¢½øÐÐÁË¿Ë¡£¬Æä¿Éת¼ÓÕµ¼Tϸ°û³ÌÐò»¯ËÀÍö¡£Ëæºó·¢ÏÖÔÚ¼¤»îµÄT¡¢BºÍ¹ÇËèϸ°ûÉϱí´ï£¬Æä°û½¬Çøº¬ÓÐÒ»¸öÃâÒßÊÜÌåÂç°±ËáÒÖÖÆ»ùÐò¡£ÇóýPD-1»ùÒòµÄÊó»á³öÏÖÀÇ´¯Ñù·çʪ²¡ºÍѪ¹ÜÇòÐÔÉöÑ×£¬Ëæ×ÅÊóÁäÔö³¤³öÏÖIgG3ΪÖ÷µÄ³Á»ý£¬ÓëÀÇ´¯MRLÊ󱨵ÀÀàËÆ¡£MRLÀÇ´¯ÊóÓÉlprÍ»±äµ¼Ö·¢²¡¼ÓËÙºÍÖ¢×´ÑÏÖØ¡£µ±2C-TCR(¿¹H-2Ld)ת»ùÒòÊóÔÚH-2b/d±³¾°ÏÂPD-1»ùÒòȱʧµÄ´¿ºÏ×ÓÌåÖУ¬³öÏÖÂýÐÔÖ²Ì忹ËÞÖ÷¼²²¡¡£ÓÉ´ËÏÔ³öPD-1ÊÇÒ»¸öTϸ°û·Ö×Ó£¬¿ÉÏÞÖÆTϸ°û»îÐÔ¡¢ÒÖÖÆÔöÖ³ºÍÌáÉýÄÍÊÜÐÔ¡£PD-1ÓÉÐÝÃßTϸ°ûµÍˮƽ±í´ï£¬Ò²·¢ÏÖһЩÂýÐÔ´«È¾²¡¶¯ÎïÄ£ÐÍÖб»Ñо¿Õß³ÆΪºÄ½ßµÄTϸ°û±í´ï¡£ÔÚ¸÷ÀàÉÏƤ°©¡¢ÑªÒº°©ºÍÆäËû¶ñÐÔÖ×ÁöµÄ»¼ÕßÑ­»·ÏµÍ³ÖдæÔÚ¸ßˮƽµÄPD-1¡£ÇÒÖ×Áö½þÈóÐÔÁÜ°Íϸ°û£¬°üÀ¨Tϸ°û£¬¾ßÓÐÖ×Áö¿¹Ô­ÌØÒìÐÔ£¬ÍƲâ¿ÉÄÜÓÉÓÚÂýÐÔ¿¹Ô­µ¼Ö¡£ÕâЩÖ×ÁöÏà¹ØPD-1±í´ïµÄЧӦϸ°ûÊǹ¦ÄÜÕÏ°­ÐÍ£¬ÆäÉúÎïѧ¹¦ÄÜ¿ÉÒÔͨ¹ýPD-1»òPD-L1×è¶Ï¿¹Ì岿·Ö»Ö¸´¡£PD-1ÊÜÌåµÄÅäÌåΪPD-L1ºÍPD-L2£¬ÅäÌå·Ö×Ó¾ùÔÚ¿¹Ô­Ìá³Êϸ°ûÖз¢ÏÖ¡£ÆäÖÐPD-L1³£ÔÚÉÏƤ°©»òÆäËûÀàÐÍ°©Ï¸°ûÖбí´ï£¬²úÉúÖ×Áö΢»·¾³¶ÔTϸ°ûµÄÒÖÖÆ×÷Óá£ÓÉÓÚPD-L1ÔÚÖ×Áö΢»·¾³Öеĸ߱í´ï£¬µ¼Ö½þÈóTϸ°û²úÉúºÄ½ßºÍ·ÖÃÚ°×½éËØ10¡£PD-L1µÄ±í´ï¿ÉÒÔ±£»¤·ÖÃÚËüµÄ°©Ï¸°ûÃâÔâCD8+Tϸ°û½éµ¼µÄÈܽâ×÷ÓᣳýÁËÓëPD-1Ï໥×÷ÓÃÍ⣬ÔÚÊóÄ£ÐÍÖз¢ÏÖPD-L1»¹¿ÉºÍCD80Ï໥×÷Ó᣼¤»îµÄTϸ°ûºÍ¿¹Ô­Ìá³Êϸ°û(ACPs)¿É±í´ïCD80£¬ÔÚÓöÓÐPD-L1ʱÆðÊÜÌåºÍÒÖÖÆÐźŵÝÖʵÄ×÷Óá£Ò²·¢ÏÖPD-L1¿É×÷ΪÊÜÌå·´´«µÝÐźÅÖÁTϸ°ûºÍÖ×Áöϸ°û£¬´Ó¶øÓ°ÏìÕâЩϸ°ûµÄ´æ»î£¬Æä»úÖÆÔÝδȷ¶¨¡£×îºó£¬PD-1ºÍPD-L1¿ÉÓÐTµ÷½Úϸ°û±í´ï²¢¿ØÖÆËüÃǹ¦ÄÜ£¬ÇÒÌìÈ»ÃâÒßÒòËØÈçNKTϸ°û¿ÉÄÜÒ²²ÎÓëPD-1/PD-L1»Ø·¡£Òò´Ë£¬PD-L1¼È¿ÉÒÔ×÷ΪÅäÌåÓÖ¿ÉÒÔ×÷ΪÊÜÌåÖ´ÐÐÃâÒßµ÷½Ú¹¦ÄÜ¡£ÒÀ¾ÝÕâЩÐÅÏ¢£¬¿ª·¢¿¹Ìå¸ÉÈźÍ×èÖ¹PD-1ºÍPD-L1¼äÏ໥×÷Óÿ´ÉÏÈ¥ÊǺÏÊʵÄ(±í 1)¡£

    

    PD-L1±í´ïºÍÖ×Áö΢»·¾³

    Ô¤²âÖ×Áö¶ÔPD-1×è¶Ï¼ÁµÄ·´Ó¦ÒÀÈ»ÊǸöÌôÕ½¡£Ã÷ÏԵģ¬Ô¤ÏÈ´æÔڵĿ¹Ö×ÁöÃâÒßÖп¹Ô­ÌØÒìÐÔCD8+Tϸ°ûÊÜPD-1/PD-L1¸ºµ÷¿Ø£¬ËùÒÔPD1×è¶Ï¼Á¶Ô´ËÓÐÁÆЧ¡£Ó*************************âÒß×éÖ¯»¯Ñ§·¨ÆÀ¹ÀPD-L1±í´ïÊÇÒ»ÖÖÔ¤²âÖ×Áö¶ÔPD-1×è¶Ï¼Á·´Ó¦Ã²ËƲ»´íµÄÉúÎï±ê¼Ç·¨¡£È»¶ø£¬ÎÞÂÛ¶ÔÖ×Áöϸ°ûÉÏ»¹ÊǽþÈóÃâÒßϸ°ûÉϵÄPD-L1µÄ±í´ï½øÐÐÆÀ¹À£¬ÔÚÓ*************************âÒß×éÖ¯»¯Ñ§·¨½øÐвâÁ¿ÊÇÒ»ÖÖ´æÔڸ߶ȱäÒìÐÔ¡¢ÒìÖÊÐԺͶ¯Ì¬±ê¼Ç·¨£¬Õâ¹ÌÓÐÊôÐÔµ¼ÖÂÆäÔÚÔ¤²âPD-1/PD-L1×è¶Ï¼ÁЧӦʱµÄ¾ÖÏÞ¡£

    ÁíÍ⣬PD-L1±í´ïϸ°ûÔÚÖ×Áö΢»·¾³µÄλÖÃÒ²ÖØÒª¡£ÔÚÒ»ÏîºÚÉ«ËØÁöµÄÑо¿ÖУ¬ÀûÓÃpembrolizumab½øÐÐÖÎÁÆ£¬Á¬Ðø²É¼¯Ö×ÁöÑù±¾·¢ÏÖÔÚÓз´Ó¦»¼ÕßÖÐÖ×ÁöÄÚCD8+Tϸ°û³öÏÖÀ©Ôö¡£ÕâЩ»¼ÕßÖеÄÔ¤ÖÎÑù±¾ÏÔʾ±í´ïPD-1ºÍPD-L1µÄCD8+Tϸ°ûÔÚ½þÈó±ßÔµ£¬¸ÃÇé¿öÒ²ÔÚËæºóµÄ»ùÓÚCD8±í´ïÔ¤²âÄ£Ð͵ÄÁíÒ»¸ö¶ÀÁ¢15Ãû²¡»¼µÄ¶ÓÁÐÖеõ½ÑéÖ¤¡£ËäÈ»Èç´Ë£¬3ÖÖÃâÒß×éÖ¯»¯Ñ§·¨¼ì²âPD-L1±í´ïµÄ·½·¨×î½ü±»FDAÅú×¼ÓÃÓÚÖ¸µ¼ÖÎÁÆÄò·ÉÏƤ°©¡¢ºÚÉ«ËØÁöºÍ·ÇϸСϸ°û·Î°©·½°¸µÄÈ·¶¨£¬Ã¿¸öÓò»Í¬µÄ·½·¨£¬²»Í¬µÄãÐֵɸѡPD-L1¹ýÁ¿±í´ï¡£ÆäËûµÄÈçVentana SP263·½·¨Ò²ÕýÔÚ¿ª·¢£¬Õâ¸öÊÇËædurvalumab(Astra Zeneca/Medimmune)Ò»Æð±»ÑÐÖƵÄ(±í 2)¡£³ýÁ˼¼ÊõµÄÌôÕ½ºÍPD-L1±í´ï¼ì²â·½·¨µÄ²»Í¬Í⣬ÿÖÖ·½·¨¿´ËÆÏÔʾ³ö±í´ïÓë·´Ó¦µÄ¹Øϵ¡£ÔÚÐí¶àÖ×Áöϸ°ûÖУ¬ÕæÕýPD-L1ÑôÐÔµÄÖ×Áöϸ°ûÊýÁ¿±ÈÀý¿ÉÄܺܵÍ;ÔÚBMSÊÔÑé±»¶¨ÒåΪDAKOÑôÐÔÖоÍ5%»ò¶àЩ¡£PD-L1ÃâÒß×éÖ¯»¯Ñ§·¨±È½ÏÀ¶Í¼ÏîÄ¿(The Blueprint PD-L1 IHC Assay Comparison Project)ÊÇËļÒÒ©Æó(AstraZeneca PLC°¢Ë¹Àû¿µ£¬Gaitherurg¸Çɪ˹±¤£¬MDÂíÀïÀ¼ÖÝ;Bristol-Myers Squibb Company°ÙʱÃÀÊ©¹ó±¦¹«Ë¾;Genentech£¬Inc.»ùÒòÌ©¿ËºÍMerck ÀäÖ×Áö)»ù±¾²»¶ÔPD-1/L1×è¶Ï¼ÁÆð·´Ó¦£¬ËùÒÔÁ˽âÇý¶¯ÃâÒßÅųýµÄ»úÖƶÔÓÚ¿ª·¢Ñ¡ÔñÐÔµÄÖÎÁƲßÂÔºÜÖØÒª¡£Ò»¸öÖØÒªµÄÈ˺ÚÉ«ËØÁöÑù±¾³õ²½Ñо¿ÏÔʾ£¬WNT/b-cateninÐźÅͨ·µÄ¼¤»îÓëTϸ°û»ùÒò±í´ïÐźŵÄȱʧÏà¹ØÁª¡£ÔÚ×Ô·¢ÐÔСÊóºÚÉ«ËØÁöÄ£ÐÍÖз¢ÏÖ£¬WNT/b-cateninÐźſ´ÉÏÈ¥ÊÇÖ×Áö¹ÌÓеģ¬ÓÃÀ´µ÷½Ú¿¹PD-L1ºÍCTLA-4ÖÎÁÆ¿¹ÐԵġ£Ò»¸öÇúÏßµÄβ²¿)¶ÔÓÚÆÀ¼ÛÁÙ´²»ñÒæ¸üΪ׼ȷ¡£ÃâÒßϵͳµÄ¶¯Ì¬±ä»¯ºÍÊÊÓ¦ÐÔʹµÃÉúÎï±ê¼ÇÎïµÄÑз¢Êܵ½ÌôÕ½£¬µ«Í¬ÑùʹµÃά³Ö¸ú½øÖ×Áö½ø»¯²½·¥³ÉΪÎÞÏÞDZÔڵĿÉÄÜ£¬Ò²Ê¹µÃÏÈÇ°´«Í³°©Ö¢ÁÆ·¨ÎÞ·¨»ñµÃµÄ³Ö¾ÃЧ¹û³ÉΪ¿ÉÄÜ¡£

    Ô­Ê¼³ö´¦£º

    Balar AV£¬ Weber JS.PD-1 and PD-L1 antibodies in cancer£º current status and future directions. Cancer Immunol Immunother. 2017 May;66(5)£º551-564
·ÖÏí:

ÓÞÓÞѧ԰ÊôÓÚ´¿Ñ§Êõ¡¢·Ç¾­ÓªÐÔרҵÍøÕ¾£¬ÎÞÈκÎÉÌÒµÐÔÖÊ£¬´ó¼Ò³öÓÚѧϰºÍ¿ÆÑÐÄ¿µÄ½øÐн»Á÷ÌÖÂÛ¡£

ÈçÓÐÉæÇÖ·¸Öø×÷ȨÈ˵İæȨµÈÐÅÏ¢£¬Ç뼰ʱÀ´ÐŸæÖª£¬ÎÒÃǽ«Á¢¿Ì´ÓÍøÕ¾ÉÏɾ³ý£¬²¢ÏòËùÓгְæȨÕßÖÂ×îÉîǸÒ⣬лл¡£